Stem cell therapy is highly effective for a small number of conditions, modestly helpful for others, and still unproven for most. The only stem cell treatment with full FDA approval is blood (hematopoietic) stem cell transplantation for cancers and disorders of the blood and immune system. Everything else, from knee injections to neurological treatments, remains experimental to varying degrees. How well stem cell therapy works depends entirely on what condition it’s treating, what type of cells are used, and how they’re delivered.
Blood Cancers: The Proven Success Story
Stem cell transplants for blood cancers like leukemia and lymphoma have the longest track record and the strongest results. These transplants replace a patient’s diseased bone marrow with healthy blood-forming stem cells, either from a donor or from the patient’s own body after treatment. Five-year overall survival rates in children with very high-risk leukemia now reach 65% for acute lymphoblastic leukemia and 74% for acute myeloid leukemia. That’s a dramatic improvement from earlier treatment eras, when those numbers were 28% and 34%, respectively.
One major factor is how much residual disease a patient has right before transplant. Children who tested negative for leftover cancer cells had five-year survival rates of roughly 68%, while those who still had detectable disease dropped to 30% for lymphoblastic leukemia and 47% for myeloid leukemia. Relapse rates followed the same pattern: around 6% for patients with no detectable disease versus 28 to 37% for those who still had cancer cells at the time of transplant. This is a mature, well-understood therapy with real but significant risks, including graft-versus-host disease, infection, and organ damage from the intensive preparation regimen.
Multiple Sclerosis: Strong Early Results
For aggressive relapsing-remitting multiple sclerosis, a specialized form of blood stem cell transplant has shown striking results. The procedure essentially resets the immune system by wiping it out with chemotherapy and rebuilding it from the patient’s own stem cells. Across multiple studies reviewed in 2023, 80 to 100% of patients remained relapse-free at five years. Several independent trials reported relapse-free survival rates of 84 to 87%, and one smaller study achieved 100% at all measured time points.
These numbers are significantly better than what most MS drugs achieve. The treatment works best in younger patients with active inflammatory disease and tends to be less effective for progressive forms of MS where nerve damage has already accumulated. It’s an intensive procedure with real short-term risks from the chemotherapy, but for the right patients, it can halt disease activity in ways that medications often cannot.
Knee Osteoarthritis: Modest Pain Relief
Stem cell injections for knee osteoarthritis are one of the most commonly marketed procedures at private clinics, but the clinical evidence is more modest than the advertising suggests. A meta-analysis of randomized controlled trials found that patients receiving stem cell injections had statistically significant pain reductions compared to control groups at 3, 6, and 12 months. The effect grew stronger over time, with the largest difference appearing at 6 and 12 months.
However, on measures of actual knee function, stiffness, and physical ability, stem cells showed no significant advantage over control treatments at most time points. Pain scores improved, but daily function scores did not meaningfully change. At 24 months, both pain and one functional score favored the stem cell group, but the overall picture is of a treatment that reduces pain without clearly restoring joint function. There’s also no evidence that stem cells regrow lost cartilage in a clinically meaningful way in these studies.
Heart Failure: Disappointing So Far
Stem cell therapy for heart failure has been one of the most studied applications in regenerative medicine, and the results have been largely underwhelming. The core idea is that injecting stem cells into damaged heart tissue might help it recover pumping strength. The most commonly measured outcome is left ventricular ejection fraction, which reflects how well the heart pumps blood with each beat.
A recent meta-analysis found that stem cell therapy produced a small, statistically nonsignificant improvement in heart pumping function. Earlier reviews reported modest gains of 3 to 6 percentage points, which were statistically detectable but considered too small to be clinically meaningful for most patients. One older analysis of 48 studies found an average improvement of about 3 percentage points. For context, a heart failure patient typically needs much larger improvements to notice a real difference in daily life. The therapy appears safe but has not delivered the transformative results researchers initially hoped for.
Type 1 Diabetes: A Single Breakthrough Case
In one of the most publicized developments in stem cell research, a 25-year-old woman with type 1 diabetes achieved complete insulin independence after receiving cells grown from her own reprogrammed stem cells. Within two and a half months of the transplant, she was producing enough insulin on her own to stop injections entirely. Her blood sugar stayed in the target range for over 98% of the day, and she maintained that result for more than a year.
This is a genuine milestone, but it’s a single patient. Separate early-stage trials using donor-derived stem cells have shown initial signs of insulin production in other patients, though long-term outcomes are still unknown. The gap between one extraordinary case report and a reliable, reproducible treatment is enormous, and it will take years of larger trials to know whether this approach works broadly.
Vision Loss: Early Safety Data Only
For age-related macular degeneration, stem cell-derived retinal tissue transplants have cleared initial safety hurdles. In patients where damaged blood vessel patches could be fully removed during surgery, visual acuity remained stable or improved over 12 months with limited side effects. Patients where removal was only partial had persistent bleeding, inflammation, and no vision improvement. These are early-phase safety trials, not efficacy studies, so the question of how well this works at scale remains open.
How Stem Cells Actually Work in the Body
Most people assume stem cells work by transforming into new tissue, replacing whatever is damaged. That does happen in blood stem cell transplants, where the cells genuinely rebuild the bone marrow and immune system. But for most other applications, the primary mechanism is different. Mesenchymal stem cells, the type used in most orthopedic and cardiac procedures, appear to work mainly by releasing signaling molecules that reduce inflammation, protect injured tissue from further damage, and encourage the body’s own repair processes.
These cells secrete a range of growth factors, immune-modulating molecules, and tiny packages of genetic material that influence surrounding cells. In animal studies of heart attacks, for example, stem cells significantly reduced inflammatory markers and cell death in heart tissue. The cells also interact with the immune system, dialing down both local and body-wide immune responses. This explains why stem cells can reduce pain and inflammation in an arthritic knee without actually regrowing cartilage. The therapeutic effect is real but often more about calming the environment than rebuilding the structure.
Safety Across Conditions
The safety profile varies dramatically depending on the type of stem cell therapy. Blood stem cell transplants for cancer carry serious risks, including life-threatening infections, organ damage from chemotherapy, and graft-versus-host disease. These are accepted because the alternative is often fatal disease.
For less intensive procedures like joint injections, the safety record is generally reassuring. A systematic review of stem cell therapy in spinal cord injury patients found no life-threatening consequences or deaths directly attributable to the cell therapy itself. No tumor formation was reported in any study, even with follow-up periods extending to six years. Allergic reactions occurred at a rate of about 2%, mostly mild (itching, local reactions). Severe adverse events, primarily things like spinal fluid leaks and wound infections, were related to the surgical delivery rather than the cells themselves. The most serious general risks of cell therapy remain blood clots, infection, and abnormal tissue growth, but in clinical trials these have been rare.
Cost of Unproven Treatments
If you’re considering stem cell therapy outside of an approved transplant program or clinical trial, the financial burden is significant. The average cost of a stem cell procedure in the United States is roughly $10,000. Knee injections typically run $5,000 to $10,000. Treatments for back pain and shoulders range from $5,000 to $15,000. Vision-related procedures start around $20,000 and go higher. Treatments marketed for autism or neurological conditions outside the U.S. generally cost $20,000 and up.
Insurance rarely covers these procedures because they lack FDA approval. The only routinely covered stem cell therapy is the hematopoietic transplant for blood cancers and immune disorders. For everything else, you’re paying out of pocket for a treatment that may provide some symptom relief but has not been proven to deliver lasting structural repair. Clinical trials, which are free to participants, offer a way to access experimental stem cell therapies with proper medical oversight and monitoring.